An interventional study of Assessment of endometrium and blood biomarkers for endometriosis diagnosis in Endometriosis (Diagnosis), Blood Biomarkers and Endometrium Biomarkers, sponsored by Dr Afchine Fazel. Status unknown at 1 site in France. Open to female participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-05-12.
Sponsored by Dr Afchine Fazel · Not applicable, Interventional, and Diagnostic
EndoSearch aims to analytically validate a cluster of specific biomarkers for endometriosis diagnosis and disease recurrence. This signature will be tested on endometrium and blood from 975 patients, divided in two groups : 550 patients affected by endometriosis and 225 patients unaffected (controls).
EndoSearch is not about drug or medical device assessment but a research study for biomarker analytical validation purpose.
Endometriosis is a very common gynecological disease affecting 10% of women of reproductive age. Main symptoms are chronic and severe pain in pelvis area and infertility in up to 40% of affected women. Currently, the only method to obtain a reliable diagnosis is the analysis of endometriotic lesions removed during surgery under general anaesthesia. There is a real need to diagnosis endometriosis non-invasively and quickly in order to improve patient management.
EndoSearch aims to analytically validate a cluster of endometrial and blood biomarkers identified in previous studies and specific for the endometriosis diagnosis and disease prognosis recurrence. During 2 years (follow up period) and 9 months (inclusion period), 15 clinical centers worldwide will recruit patients and collect biological samples and personal and clinical data from these patients. The biological samples will be processed at Endodiag labs, Paris, France though lab biotechnology techniques. Results will allow the assessment of sensibility and specificity (NPV and PPV) of the biomarker signature for endometriosis diagnosis and disease recurrence.
925 studies on the registry are indexed under Endometriosis; 264 are open to participants now.
This study's planned enrollment of 975 is above the median of 65 across 539 interventional studies indexed under Endometriosis.
Browse Endometriosis studies →This is the only study on the registry with Dr Afchine Fazel as lead sponsor.
Counted across the registry records on this site, refreshed daily.
Inclusion Criteria for endometriosis patients :
Inclusion Criteria for Healthy voluntary patients:
Exclusion Criteria for endometriosis patients :
Exclusion Criteria for Healthy voluntary patients
EndoSearch will conduct on only one cohort divided in two groups : patients affected by endometriosis and patient unaffected (controls). All of these patients need a laparoscopic surgery for endometriosis indication (endometriosis group) or another indication which is not endometriosis (controls). However, nothing in the surgery or the patient medical care will be different between the two groups : patients will be treated exactly the same.
Other: Assessment of endometrium and blood biomarkers for endometriosis diagnosis
Biological samples will be collected from patients, sent to Endodiag, Paris, in France and be processed through IHC and molecular biology techniques to assess the ability of the identified biomarkers signature to diagnose and prognose endometriosis.
Sensibility for endometriosis diagnosis (probability of detection)
Measurement of the proportion of positives patient that are correctly identified as such for the endometriosis diagnosis.
Time frame: Comparison between diagnosis lab result and anatomopathologist diagnosis at the end of inclusion phase (9 months after 1st patient inclusion)
Specificity for endometriosis diagnosis
Measurement of the proportion of negatives patient that are correctly identified as such for the endometriosis diagnosis
Time frame: Comparison between diagnosis lab result and anatomopathologist diagnosis at the end of inclusion phase (9 months after 1st patient inclusion)
Sensibility for endometriosis recurrence prognostic (probability of detection)
Measurement of the proportion of positives patient that are correctly identified as such for the endometriosis recurrence prognostic.
Time frame: Comparison between recurrence lab result and eCRF data on recurrence at the end of study (2 years and 9 months)
Specificity for endometriosis recurrence prognostic
Measurement of the proportion of negatives patient that are correctly identified as such for the endometriosis recurrence prognostic.
Time frame: Comparison between recurrence lab result and eCRF data on recurrence at the end of study (2 years and 9 months)
Plan to share: No
No publications or documents are linked to this record.
This study is status unknown, as verified in May 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.